|
| 36940615 | Trabectedin modulates macrophage polarization in the tumor-microenvironment. Role of K<sub>V</sub>1.3 and K<sub>V</sub>1.5 channels. | Biomed Pharmacother | 2023 |
| 36996147 | Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC-MS/MS. | PLoS One | 2023 |
| 35231500 | Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis. | Antiviral Res | 2022 |
| 35806460 | Plocabulin, a Novel Tubulin Inhibitor, Has Potent Antitumour Activity in Patient-Derived Xenograft Models of Soft Tissue Sarcoma. | Int J Mol Sci | 2022 |
| 35012962 | Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19. | Life Sci Alliance | 2022 |
| 35042701 | Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients. | Drug Metab Dispos | 2022 |
| 34066159 | Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma. | Cancers (Basel) | 2021 |
| 33495306 | Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. | Science | 2021 |
| 34075384 | Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization. | medRxiv | 2021 |
| 32264921 | CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110. | J Hematol Oncol | 2020 |
| 31812675 | Generation of endoplasmic reticulum stress and inhibition of autophagy by plitidepsin induces proteotoxic apoptosis in cancer cells. | Biochem Pharmacol | 2020 |
| 32711367 | Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors. | Transl Oncol | 2020 |
| 30831452 | Development of a new method for the quantitation of metabolites in the absence of chemically synthetized authentic standards. | J Pharm Biomed Anal | 2019 |
| 29127040 | Improved pharmacokinetic profile of lipophilic anti-cancer drugs using ανβ3-targeted polyurethane-polyurea nanoparticles. | Nanomedicine | 2018 |
| 29974200 | Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of <sup>14</sup>C-plitidepsin. | Cancer Chemother Pharmacol | 2018 |
| 29883879 | Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine. | J Pharm Biomed Anal | 2018 |
| 29415678 | Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells. | BMC Cancer | 2018 |
| 29440297 | MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding <i>In Vivo</i> Activity against HER2-Expressing Tumors. | Mol Cancer Ther | 2018 |
| 27540138 | Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone. | Haematologica | 2017 |
| 28662481 | Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine. | J Pharm Biomed Anal | 2017 |
| 26871278 | Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM01183 (lurbinectedin), a novel antineoplastic agent, in mouse, rat, dog, Cynomolgus monkey and mini-pig plasma. | J Pharm Biomed Anal | 2016 |
| 27697767 | Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus. | Cancer Res | 2016 |
| 27630271 | Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells. | Mol Cancer Ther | 2016 |
| 27780828 | Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models. | Dis Model Mech | 2016 |
| 25681727 | Enhanced in vivo therapeutic efficacy of plitidepsin-loaded nanocapsules decorated with a new poly-aminoacid-PEG derivative. | Int J Pharm | 2015 |
| 26295985 | HPLC-MS/MS method to measure trabectedin in tumors: preliminary PK study in a mesothelioma xenograft model. | Bioanalysis | 2015 |
| 24486569 | PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors. | Biochem Pharmacol | 2014 |
| 24758355 | Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis. | BMC Cancer | 2014 |
| 24614852 | Use of air stacking and abdominal compression for cough assistance in people with complete tetraplegia. | Spinal Cord | 2014 |
| 24287622 | Nano-encapsulation of plitidepsin: in vivo pharmacokinetics, biodistribution, and efficacy in a renal xenograft tumor model. | Pharm Res | 2014 |
| 23591661 | A new potential nano-oncological therapy based on polyamino acid nanocapsules. | J Control Release | 2013 |
| 23697951 | c-Jun N-terminal kinase phosphorylation is a biomarker of plitidepsin activity. | Mar Drugs | 2013 |
| 22896654 | Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. | Clin Cancer Res | 2012 |
| 22852480 | Comparison of pharmacokinetic profiles of PM02734 loaded lipid nanoparticles and cyclodextrins: in vitro and in vivo characterization. | J Biomed Nanotechnol | 2012 |
| 21330323 | Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. | Haematologica | 2011 |
| 20977459 | PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. | Br J Pharmacol | 2010 |
| 19020308 | Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. | Blood | 2009 |
| 19427997 | Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines. | Biochem Pharmacol | 2009 |
| 19426702 | In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping. | Biochem Pharmacol | 2009 |
| 18593922 | Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. | Cancer Res | 2008 |
| 19055929 | [Risk factors for prolonged mechanical ventilation after cardiac surgery in children]. | Med Intensiva | 2008 |
| 16497567 | Quantitative analysis of Variolin analog (PM01218) in mouse and rat plasma by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. | J Chromatogr B Analyt Technol Biomed Life Sci | 2006 |
| 16921565 | Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM02734, a novel antineoplastic agent, in dog plasma. | Rapid Commun Mass Spectrom | 2006 |
| 15702485 | Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM00104, a novel antineoplastic agent, in mouse, rat, dog, and human plasma. | Rapid Commun Mass Spectrom | 2005 |
| 16461533 | The application of image quality measurements for digital angiography. | Radiat Prot Dosimetry | 2005 |
| 16461530 | Evaluation of risk of deterministic effects in fluoroscopically guided procedures. | Radiat Prot Dosimetry | 2005 |
| 14599541 | Computer-assisted enhanced volumetric segmentation magnetic resonance imaging data using a mixture of artificial neural networks. | Magn Reson Imaging | 2003 |
| 12888201 | Validation of a sensitive assay for thiocoraline in mouse plasma using liquid chromatography-tandem mass spectrometry. | J Chromatogr B Analyt Technol Biomed Life Sci | 2003 |
| 12876692 | Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of Aplidin, a novel marine-derived antineoplastic agent, in human plasma. | Rapid Commun Mass Spectrom | 2003 |
| 11968136 | Monitoring acute inflammatory processes in mouse muscle by MR imaging and spectroscopy: a comparison with pathological results. | NMR Biomed | 2002 |